University of Texas's MD Anderson and Yingli Pharma Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs
January 21, 2022
January 21, 2022
HOUSTON, Texas, Jan. 21 (TNSPar) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 20, 2022:
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
The five-year collaboration brings together Yingli's experience in medicinal chemistry with MD Anderson's compr . . .
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
The five-year collaboration brings together Yingli's experience in medicinal chemistry with MD Anderson's compr . . .